Clinical trial ARTEMIDE-01
A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001)
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2021-000857-23 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04995523 |
Last update |